354: Uncertainty in CRISPR world and the start of more M&A

Jason Mast, a STAT reporter specializing in gene therapy, brings a wealth of knowledge to the discussion. He shares insights from the recent American Society of Cell and Gene Therapy meeting, highlighting both excitement and uncertainty in the gene editing field. The conversation touches on recent mergers, including Sanofi's acquisition of Vigil Neurosciences, and the changing landscape fueled by leadership shifts at Novo Nordisk. They also delve into the FDA's review of cancer drugs, navigating both data challenges and clinical implications.